Fresh analysis suggests that patients who stop using new GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight far faster than those who halt conventional lifestyle programs.
Published data in a leading health publication demonstrates that while obese individuals can lose a large proportion of their body weight while on the medication, the mass is regained at an average rate of 0.8 kg per month once they quit.
"Users purchasing such medications need to be informed of the potential of quick weight regain when the therapy ends," cautioned lead investigator Dr. Susan Jebb.
Such speed of regain means a return to starting weight within about a year and a half.
Weighing Treatments
The study, which looked at dozens of trials involving thousands of participants, contrasted the effects of GLP-1 agonists with conventional dieting.
Researchers note that people who shed pounds through dieting typically experience a slower weight regain—approximately 0.1 kg a month—after stopping.
The Reason for the Quick Rebound
Experts suggest the mode of action of the jabs explains the heightened weight return.
GLP-1 drugs copy a natural hormone called GLP-1, which helps regulate feelings of fullness.
"Long-term administration of GLP-1 levels far above than normal may cause the system to generate a reduced amount of its endogenous hormone, and could diminish sensitivity to its effects," noted Dr. Adam Collins, a dietetics expert.
"Withdrawal of this hormone supplement results in hunger is uncontrolled, making overeating far more likely."
A Lifelong Condition?
Medical guidelines advise the jabs for individuals with weight-linked medical conditions, alongside prescribed lifestyle changes.
A number of clinicians argue that, given the likelihood of relapse, the treatment might need to be life-long.
This opinion is supported by pharmaceutical companies, who note that the results "emphasize the chronic character of obesity," comparing it to managing diseases like high blood pressure.
User Experiences
Individuals who have come off the jabs describe a sudden return of cravings.
"I experienced something activating and I was suddenly ravenous," recalled a patient.
This challenge is compounded if patients have not developed permanent lifestyle or habit changes during therapy.
Growing Use
Survey data show that a significant number of adults in the UK have tried these injections in the past year, with demand continuing to grow.
- Adoption is more common among women compared to males.
- The 40s and 50s age group shows the highest usage rates.
- A large proportion access the drugs through private prescriptions rather than the NHS.
Finally, researchers stress that while these medications are powerful agents for weight loss, they are not a permanent solution and lasting health benefits likely depends on ongoing behavioural changes.
